Remark: Providers should consider LMWH using doses based on actual body weight (see recommendation 1) and not monitoring anti factor Xa concentrations, similar to the approach used in nonobese patients. Recommendation 9. For patients receiving DOAC therapy for the treatment of VTE, the ASH guideline panel suggests against measuring the DOAC anticoagulant effect during management of bleeding (conditional recommendation based on very low certainty in the evidence about effects ). Transitions between anticoagulants Recommendation 10. For patients transitioning from DOAC to VKA, the ASH guideline panel suggests overlapping DOAC and VKA therapy until the INR is within the therapeutic range over using LMWH or UFH bridging therapy (conditional recommen- dation based on very low certainty in the evidence about effects ). Use of specialized AMSs Recommendation 11. For patients receiving anticoagulation therapy for treatment of VTE, the ASH guideline panel suggests using specialized AMS care rather than care provided by the patient s usual health care provider (conditional recommendation based on very low certainty in the evidence about effects ). Structured patient education Recommendation 12. For patients receiving oral anticoagula- tion therapy for VTE treatment, the ASH guideline panel suggests using supplementary patient education in addition to basic education (conditional recommendation based on very low certainty in the evidence about effects ). Efforts to improve anticoagulant-medication adherence Recommendation 13a. For patients receiving anticoagula- tion therapy for treatment of VTE, the ASH guideline panel suggests against using a daily lottery (between a 1-in-5 and 1-in- 100 chance of a monetary reward each day if a pill compartment on a sophisticated electronic-medication-monitoring system is accessed) to improve medication adherence (conditional rec- ommendation based on very low certainty in the evidence about effects ). Recommendation 13b. 